Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Jun;57(6):672–681. doi: 10.1136/jnnp.57.6.672

Parkinson's disease.

C D Marsden 1
PMCID: PMC1072968  PMID: 7755681

Full text

PDF
672

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbeau A. The clinical physiology of side effects in long-term L-DOPA therapy. Adv Neurol. 1974;5:347–365. [PubMed] [Google Scholar]
  2. Beattie A., Caird F. I. The occupational therapist and the patient with Parkinson's disease. Br Med J. 1980 Jun 7;280(6228):1354–1355. doi: 10.1136/bmj.280.6228.1354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Benabid A. L., Pollak P., Gervason C., Hoffmann D., Gao D. M., Hommel M., Perret J. E., de Rougemont J. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet. 1991 Feb 16;337(8738):403–406. doi: 10.1016/0140-6736(91)91175-t. [DOI] [PubMed] [Google Scholar]
  4. Berkowitz D. M., McCallum R. W. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther. 1980 Mar;27(3):414–420. doi: 10.1038/clpt.1980.55. [DOI] [PubMed] [Google Scholar]
  5. Blin J., Bonnet A. M., Agid Y. Does levodopa aggravate Parkinson's disease? Neurology. 1988 Sep;38(9):1410–1416. doi: 10.1212/wnl.38.9.1410. [DOI] [PubMed] [Google Scholar]
  6. Bonnet A. M., Loria Y., Saint-Hilaire M. H., Lhermitte F., Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology. 1987 Sep;37(9):1539–1542. doi: 10.1212/wnl.37.9.1539. [DOI] [PubMed] [Google Scholar]
  7. Brooks D. J. PET studies on the early and differential diagnosis of Parkinson's disease. Neurology. 1993 Dec;43(12 Suppl 6):S6–16. [PubMed] [Google Scholar]
  8. Brown R. G., MacCarthy B., Gotham A. M., Der G. J., Marsden C. D. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med. 1988 Feb;18(1):49–55. doi: 10.1017/s0033291700001872. [DOI] [PubMed] [Google Scholar]
  9. Brown R. G., Marsden C. D. How common is dementia in Parkinson's disease? Lancet. 1984 Dec 1;2(8414):1262–1265. doi: 10.1016/s0140-6736(84)92807-1. [DOI] [PubMed] [Google Scholar]
  10. Brown R. G., Marsden C. D., Quinn N., Wyke M. A. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1984 May;47(5):454–465. doi: 10.1136/jnnp.47.5.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bush D. F., Liss C. L., Morton A. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group. Neurology. 1989 Nov;39(11 Suppl 2):101–105. [PubMed] [Google Scholar]
  12. Bushmann M., Dobmeyer S. M., Leeker L., Perlmutter J. S. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology. 1989 Oct;39(10):1309–1314. doi: 10.1212/wnl.39.10.1309. [DOI] [PubMed] [Google Scholar]
  13. Byrne E. J., Lennox G., Lowe J., Godwin-Austen R. B. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):709–717. doi: 10.1136/jnnp.52.6.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Cantello R., Gilli M., Riccio A., Bergamasco B. Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study. J Neurol Neurosurg Psychiatry. 1986 Oct;49(10):1182–1190. doi: 10.1136/jnnp.49.10.1182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cedarbaum J. M., Breck L., Kutt H., McDowell F. H. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease. Neurology. 1987 Feb;37(2):233–241. doi: 10.1212/wnl.37.2.233. [DOI] [PubMed] [Google Scholar]
  16. Clarke C. E. Mortality from Parkinson's disease in England and Wales 1921-89. J Neurol Neurosurg Psychiatry. 1993 Jun;56(6):690–693. doi: 10.1136/jnnp.56.6.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Crystal H. A., Dickson D. W., Lizardi J. E., Davies P., Wolfson L. I. Antemortem diagnosis of diffuse Lewy body disease. Neurology. 1990 Oct;40(10):1523–1528. doi: 10.1212/wnl.40.10.1523. [DOI] [PubMed] [Google Scholar]
  18. Curtis L., Lees A. J., Stern G. M., Marmot M. G. Effect of L-dopa on course of Parkinson's disease. Lancet. 1984 Jul 28;2(8396):211–212. doi: 10.1016/s0140-6736(84)90493-8. [DOI] [PubMed] [Google Scholar]
  19. Diederich N., Goetz C. G., Stebbins G. T., Klawans H. L., Nittner K., Koulosakis A., Sanker P., Sturm V. Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology. 1992 Jul;42(7):1311–1314. doi: 10.1212/wnl.42.7.1311. [DOI] [PubMed] [Google Scholar]
  20. Durso R., Isaac K., Perry L., Saint-Hilaire M., Feldman R. G. Age influences magnitude but not duration of response to levodopa. J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):65–68. doi: 10.1136/jnnp.56.1.65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Edwards L. L., Quigley E. M., Pfeiffer R. F. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology. 1992 Apr;42(4):726–732. doi: 10.1212/wnl.42.4.726. [DOI] [PubMed] [Google Scholar]
  22. Fabbrini G., Juncos J., Mouradian M. M., Serrati C., Chase T. N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol. 1987 Apr;21(4):370–376. doi: 10.1002/ana.410210409. [DOI] [PubMed] [Google Scholar]
  23. Factor S. A., Weiner W. J. Early combination therapy with bromocriptine and levodopa in Parkinson's disease. Mov Disord. 1993 Jul;8(3):257–262. doi: 10.1002/mds.870080302. [DOI] [PubMed] [Google Scholar]
  24. Fahn S. Fetal-tissue transplants in Parkinson's disease. N Engl J Med. 1992 Nov 26;327(22):1589–1590. doi: 10.1056/NEJM199211263272209. [DOI] [PubMed] [Google Scholar]
  25. Fitzmaurice H., Fowler C. J., Rickards D., Kirby R. S., Quinn N. P., Marsden C. D., Milroy E. J., Turner-Warwick R. T. Micturition disturbance in Parkinson's disease. Br J Urol. 1985 Dec;57(6):652–656. doi: 10.1111/j.1464-410x.1985.tb07025.x. [DOI] [PubMed] [Google Scholar]
  26. Fox M. W., Ahlskog J. E., Kelly P. J. Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients. J Neurosurg. 1991 Nov;75(5):723–730. doi: 10.3171/jns.1991.75.5.0723. [DOI] [PubMed] [Google Scholar]
  27. Frankel J. P., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96–101. doi: 10.1136/jnnp.53.2.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Kriek E., Qi J. X., Lone T., Zhang Y. B., Snyder J. A., Wells T. H. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 1992 Nov 26;327(22):1549–1555. doi: 10.1056/NEJM199211263272202. [DOI] [PubMed] [Google Scholar]
  29. Friedman J. H., Lannon M. C. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology. 1989 Sep;39(9):1219–1221. doi: 10.1212/wnl.39.9.1219. [DOI] [PubMed] [Google Scholar]
  30. Giladi N., McMahon D., Przedborski S., Flaster E., Guillory S., Kostic V., Fahn S. Motor blocks in Parkinson's disease. Neurology. 1992 Feb;42(2):333–339. doi: 10.1212/wnl.42.2.333. [DOI] [PubMed] [Google Scholar]
  31. Goetz C. G., De Long M. R., Penn R. D., Bakay R. A. Neurosurgical horizons in Parkinson's disease. Neurology. 1993 Jan;43(1):1–7. doi: 10.1212/wnl.43.1_part_1.1. [DOI] [PubMed] [Google Scholar]
  32. Goetz C. G., Tanner C. M., Levy M., Wilson R. S., Garron D. C. Pain in Parkinson's disease. Mov Disord. 1986;1(1):45–49. doi: 10.1002/mds.870010106. [DOI] [PubMed] [Google Scholar]
  33. Golbe L. I., Lieberman A. N., Muenter M. D., Ahlskog J. E., Gopinathan G., Neophytides A. N., Foo S. H., Duvoisin R. C. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease. Clin Neuropharmacol. 1988 Feb;11(1):45–55. doi: 10.1097/00002826-198802000-00004. [DOI] [PubMed] [Google Scholar]
  34. Gotham A. M., Brown R. G., Marsden C. D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain. 1988 Apr;111(Pt 2):299–321. doi: 10.1093/brain/111.2.299. [DOI] [PubMed] [Google Scholar]
  35. Gotham A. M., Brown R. G., Marsden C. D. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 1986 Apr;49(4):381–389. doi: 10.1136/jnnp.49.4.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Grimes J. D., Delgado M. R. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease. Clin Neuropharmacol. 1985;8(1):73–77. [PubMed] [Google Scholar]
  37. Hardie R. J., Lees A. J., Stern G. M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984 Jun;107(Pt 2):487–506. doi: 10.1093/brain/107.2.487. [DOI] [PubMed] [Google Scholar]
  38. Horstink M. W., Zijlmans J. C., Pasman J. W., Berger H. J., Korten J. J., van 't Hof M. A. Which risk factors predict the levodopa response in fluctuating Parkinson's disease? Ann Neurol. 1990 May;27(5):537–543. doi: 10.1002/ana.410270514. [DOI] [PubMed] [Google Scholar]
  39. Horstink M. W., Zijlmans J. C., Pasman J. W., Berger H. J., van't Hof M. A. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry. 1990 Mar;53(3):224–226. doi: 10.1136/jnnp.53.3.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Hughes A. J., Bishop S., Kleedorfer B., Turjanski N., Fernandez W., Lees A. J., Stern G. M. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993 Apr;8(2):165–170. doi: 10.1002/mds.870080208. [DOI] [PubMed] [Google Scholar]
  41. Hughes A. J., Daniel S. E., Blankson S., Lees A. J. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993 Feb;50(2):140–148. doi: 10.1001/archneur.1993.00540020018011. [DOI] [PubMed] [Google Scholar]
  42. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Hutton J. T., Morris J. L., Bush D. F., Smith M. E., Liss C. L., Reines S. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease. Neurology. 1989 Nov;39(11 Suppl 2):67–73. [PubMed] [Google Scholar]
  44. Hutton J. T., Morris J. L. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease. Neurology. 1992 Jan;42(1 Suppl 1):51–60. [PubMed] [Google Scholar]
  45. Juncos J. L., Engber T. M., Raisman R., Susel Z., Thibaut F., Ploska A., Agid Y., Chase T. N. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol. 1989 May;25(5):473–478. doi: 10.1002/ana.410250509. [DOI] [PubMed] [Google Scholar]
  46. Koller W. C., Glatt S., Vetere-Overfield B., Hassanein R. Falls and Parkinson's disease. Clin Neuropharmacol. 1989 Apr;12(2):98–105. doi: 10.1097/00002826-198904000-00003. [DOI] [PubMed] [Google Scholar]
  47. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 1991 Feb;41(2 ):202–205. doi: 10.1212/wnl.41.2_part_1.202. [DOI] [PubMed] [Google Scholar]
  48. Kurth M. C., Tetrud J. W., Irwin I., Lyness W. H., Langston J. W. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: a pilot study. Neurology. 1993 May;43(5):1036–1039. doi: 10.1212/wnl.43.5.1036. [DOI] [PubMed] [Google Scholar]
  49. Laitinen L. V., Bergenheim A. T., Hariz M. I. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg. 1992 Jan;76(1):53–61. doi: 10.3171/jns.1992.76.1.0053. [DOI] [PubMed] [Google Scholar]
  50. Lang A. E., Johnson K. Akathisia in idiopathic Parkinson's disease. Neurology. 1987 Mar;37(3):477–481. doi: 10.1212/wnl.37.3.477. [DOI] [PubMed] [Google Scholar]
  51. Langtry H. D., Clissold S. P. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs. 1990 Mar;39(3):491–506. doi: 10.2165/00003495-199039030-00009. [DOI] [PubMed] [Google Scholar]
  52. Lau E., Waterman K., Glover R., Schulzer M., Calne D. B. Effect of antacid on levodopa therapy. Clin Neuropharmacol. 1986;9(5):477–479. doi: 10.1097/00002826-198610000-00009. [DOI] [PubMed] [Google Scholar]
  53. LeWitt P. A., Ward C. D., Larsen T. A., Raphaelson M. I., Newman R. P., Foster N., Dambrosia J. M., Calne D. B. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology. 1983 Aug;33(8):1009–1014. doi: 10.1212/wnl.33.8.1009. [DOI] [PubMed] [Google Scholar]
  54. Lees A. J., Shaw K. M., Kohout L. J., Stern G. M., Elsworth J. D., Sandler M., Youdim M. B. Deprenyl in Parkinson's disease. Lancet. 1977 Oct 15;2(8042):791–795. doi: 10.1016/s0140-6736(77)90725-5. [DOI] [PubMed] [Google Scholar]
  55. Lees A. J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain. 1983 Jun;106(Pt 2):257–270. doi: 10.1093/brain/106.2.257. [DOI] [PubMed] [Google Scholar]
  56. Lesser R. P., Fahn S., Snider S. R., Cote L. J., Isgreen W. P., Barrett R. E. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology. 1979 Sep;29(9 Pt 1):1253–1260. doi: 10.1212/wnl.29.9_part_1.1253. [DOI] [PubMed] [Google Scholar]
  57. Lhermitte F., Agid Y., Signoret J. L. Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol. 1978 May;35(5):261–263. doi: 10.1001/archneur.1978.00500290007002. [DOI] [PubMed] [Google Scholar]
  58. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., Leenders K. L., Sawle G., Rothwell J. C., Marsden C. D. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990 Feb 2;247(4942):574–577. doi: 10.1126/science.2105529. [DOI] [PubMed] [Google Scholar]
  59. Luquin M. R., Scipioni O., Vaamonde J., Gershanik O., Obeso J. A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord. 1992;7(2):117–124. doi: 10.1002/mds.870070204. [DOI] [PubMed] [Google Scholar]
  60. Marconi R., Lefebvre-Caparros D., Bonnet A. M., Vidailhet M., Dubois B., Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord. 1994 Jan;9(1):2–12. doi: 10.1002/mds.870090103. [DOI] [PubMed] [Google Scholar]
  61. Marsden C. D., Parkes J. D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet. 1976 Feb 7;1(7954):292–296. doi: 10.1016/s0140-6736(76)91416-1. [DOI] [PubMed] [Google Scholar]
  62. Marsden C. D., Parkes J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977 Feb 12;1(8007):345–349. doi: 10.1016/s0140-6736(77)91146-1. [DOI] [PubMed] [Google Scholar]
  63. Mathers S. E., Kempster P. A., Law P. J., Frankel J. P., Bartram C. I., Lees A. J., Stern G. M., Swash M. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol. 1989 Oct;46(10):1061–1064. doi: 10.1001/archneur.1989.00520460037010. [DOI] [PubMed] [Google Scholar]
  64. McKeith I. G., Perry R. H., Fairbairn A. F., Jabeen S., Perry E. K. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med. 1992 Nov;22(4):911–922. doi: 10.1017/s0033291700038484. [DOI] [PubMed] [Google Scholar]
  65. Melamed E., Bitton V., Zelig O. Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology. 1986 Jan;36(1):100–103. doi: 10.1212/wnl.36.1.100. [DOI] [PubMed] [Google Scholar]
  66. Menza M. A., Sage J., Marshall E., Cody R., Duvoisin R. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord. 1990;5(2):148–151. doi: 10.1002/mds.870050210. [DOI] [PubMed] [Google Scholar]
  67. Montastruc J. L., Rascol O., Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):773–775. doi: 10.1136/jnnp.52.6.773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Mouradian M. M., Heuser I. J., Baronti F., Fabbrini G., Juncos J. L., Chase T. N. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol. 1989 May;25(5):523–526. doi: 10.1002/ana.410250521. [DOI] [PubMed] [Google Scholar]
  69. Mouradian M. M., Juncos J. L., Fabbrini G., Schlegel J., Bartko J. J., Chase T. N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol. 1988 Sep;24(3):372–378. doi: 10.1002/ana.410240304. [DOI] [PubMed] [Google Scholar]
  70. Muenter M. D., Tyce G. M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc. 1971 Apr;46(4):231–239. [PubMed] [Google Scholar]
  71. Mutch W. J., Dingwall-Fordyce I., Downie A. W., Paterson J. G., Roy S. K. Parkinson's disease in a Scottish city. Br Med J (Clin Res Ed) 1986 Feb 22;292(6519):534–536. doi: 10.1136/bmj.292.6519.534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Nissenbaum H., Quinn N. P., Brown R. G., Toone B., Gotham A. M., Marsden C. D. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med. 1987 Nov;17(4):899–904. doi: 10.1017/s0033291700000702. [DOI] [PubMed] [Google Scholar]
  73. Nutt J. G., Gancher S. T., Woodward W. R. Motor fluctuations in Parkinson's disease. Ann Neurol. 1989 Jun;25(6):633–634. doi: 10.1002/ana.410250619. [DOI] [PubMed] [Google Scholar]
  74. Nutt J. G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 1990 Feb;40(2):340–345. doi: 10.1212/wnl.40.2.340. [DOI] [PubMed] [Google Scholar]
  75. Nutt J. G. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol. 1987 Oct;22(4):535–540. doi: 10.1002/ana.410220415. [DOI] [PubMed] [Google Scholar]
  76. Palmer S. S., Mortimer J. A., Webster D. D., Bistevins R., Dickinson G. L. Exercise therapy for Parkinson's disease. Arch Phys Med Rehabil. 1986 Oct;67(10):741–745. doi: 10.1016/0003-9993(86)90007-9. [DOI] [PubMed] [Google Scholar]
  77. Perry R. H., Irving D., Blessed G., Fairbairn A., Perry E. K. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci. 1990 Feb;95(2):119–139. doi: 10.1016/0022-510x(90)90236-g. [DOI] [PubMed] [Google Scholar]
  78. Pezzoli G., Tesei S., Ferrante C., Cossutta E., Zecchinelli A., Scarlato G. Madopar HBS in fluctuating parkinsonian patients: two-year treatment. Mov Disord. 1988;3(1):37–45. doi: 10.1002/mds.870030106. [DOI] [PubMed] [Google Scholar]
  79. Pincus J. H., Barry K. Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology. 1988 Mar;38(3):481–483. doi: 10.1212/wnl.38.3.481. [DOI] [PubMed] [Google Scholar]
  80. Poewe W. H., Lees A. J., Stern G. M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology. 1986 Nov;36(11):1528–1530. doi: 10.1212/wnl.36.11.1528. [DOI] [PubMed] [Google Scholar]
  81. Quinn N. P., Koller W. C., Lang A. E., Marsden C. D. Painful Parkinson's disease. Lancet. 1986 Jun 14;1(8494):1366–1369. doi: 10.1016/s0140-6736(86)91674-0. [DOI] [PubMed] [Google Scholar]
  82. Quinn N., Critchley P., Marsden C. D. Young onset Parkinson's disease. Mov Disord. 1987;2(2):73–91. doi: 10.1002/mds.870020201. [DOI] [PubMed] [Google Scholar]
  83. Rajput A. H., Rozdilsky B., Rajput A. Accuracy of clinical diagnosis in parkinsonism--a prospective study. Can J Neurol Sci. 1991 Aug;18(3):275–278. doi: 10.1017/s0317167100031814. [DOI] [PubMed] [Google Scholar]
  84. Riley D. E., Lang A. E. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology. 1993 Aug;43(8):1459–1464. doi: 10.1212/wnl.43.8.1459. [DOI] [PubMed] [Google Scholar]
  85. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 1987 May;37(5):826–828. doi: 10.1212/wnl.37.5.826. [DOI] [PubMed] [Google Scholar]
  86. Rinne U. K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology. 1989 Mar;39(3):336–339. doi: 10.1212/wnl.39.3.336. [DOI] [PubMed] [Google Scholar]
  87. Robertson S. J., Thomson F. Speech therapy in Parkinson's disease: a study of the efficacy ad long term effects of intensive treatment. Br J Disord Commun. 1984 Dec;19(3):213–224. doi: 10.3109/13682828409029837. [DOI] [PubMed] [Google Scholar]
  88. Rogers D., Lees A. J., Smith E., Trimble M., Stern G. M. Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain. 1987 Jun;110(Pt 3):761–776. doi: 10.1093/brain/110.3.761. [DOI] [PubMed] [Google Scholar]
  89. Roos R. A., Vredevoogd C. B., van der Velde E. A. Response fluctuations in Parkinson's disease. Neurology. 1990 Sep;40(9):1344–1346. doi: 10.1212/wnl.40.9.1344. [DOI] [PubMed] [Google Scholar]
  90. Sage J. I., Trooskin S., Sonsalla P. K., Heikkila R., Duvoisin R. C. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol. 1988 Jul;24(1):87–89. doi: 10.1002/ana.410240116. [DOI] [PubMed] [Google Scholar]
  91. Scholz E., Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci. 1985;235(1):60–64. doi: 10.1007/BF00380972. [DOI] [PubMed] [Google Scholar]
  92. Scott S., Caird F. I. Speech therapy for Parkinson's disease. J Neurol Neurosurg Psychiatry. 1983 Feb;46(2):140–144. doi: 10.1136/jnnp.46.2.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Shaw K. M., Lees A. J., Stern G. M. The impact of treatment with levodopa on Parkinson's disease. Q J Med. 1980;49(195):283–293. [PubMed] [Google Scholar]
  94. Spencer D. D., Robbins R. J., Naftolin F., Marek K. L., Vollmer T., Leranth C., Roth R. H., Price L. H., Gjedde A., Bunney B. S. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med. 1992 Nov 26;327(22):1541–1548. doi: 10.1056/NEJM199211263272201. [DOI] [PubMed] [Google Scholar]
  95. Steiger M. J., Quinn N. P., Toone B., Marsden C. D. Off-period screaming accompanying motor fluctuations in Parkinson's disease. Mov Disord. 1991;6(1):89–90. doi: 10.1002/mds.870060120. [DOI] [PubMed] [Google Scholar]
  96. Stein M. B., Heuser I. J., Juncos J. L., Uhde T. W. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990 Feb;147(2):217–220. doi: 10.1176/ajp.147.2.217. [DOI] [PubMed] [Google Scholar]
  97. Steur E. N. Increase of Parkinson disability after fluoxetine medication. Neurology. 1993 Jan;43(1):211–213. doi: 10.1212/wnl.43.1_part_1.211. [DOI] [PubMed] [Google Scholar]
  98. Thomas J. E., Cascino T. L., Earle J. D. Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology. 1985 Jan;35(1):1–7. doi: 10.1212/wnl.35.1.1. [DOI] [PubMed] [Google Scholar]
  99. Wade D. T., Hewer R. L. Epidemiology of some neurological diseases with special reference to work load on the NHS. Int Rehabil Med. 1987;8(3):129–137. doi: 10.3109/03790798709166197. [DOI] [PubMed] [Google Scholar]
  100. Weiner W. J., Factor S. A., Sanchez-Ramos J. R., Singer C., Sheldon C., Cornelius L., Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology. 1993 Jan;43(1):21–27. doi: 10.1212/wnl.43.1_part_1.21. [DOI] [PubMed] [Google Scholar]
  101. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., Björklund A., Lindvall O., Langston J. W. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N Engl J Med. 1992 Nov 26;327(22):1556–1563. doi: 10.1056/NEJM199211263272203. [DOI] [PubMed] [Google Scholar]
  102. Wolters E. C., Hurwitz T. A., Mak E., Teal P., Peppard F. R., Remick R., Calne S., Calne D. B. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology. 1990 May;40(5):832–834. doi: 10.1212/wnl.40.5.832. [DOI] [PubMed] [Google Scholar]
  103. Wooten G. F. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol. 1988 Sep;24(3):363–365. doi: 10.1002/ana.410240302. [DOI] [PubMed] [Google Scholar]
  104. de Smet Y., Ruberg M., Serdaru M., Dubois B., Lhermitte F., Agid Y. Confusion, dementia and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1982 Dec;45(12):1161–1164. doi: 10.1136/jnnp.45.12.1161. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES